On October 22, 2015, Wu, Frank published a patent.Synthetic Route of 74904-29-3 The title of the patent was Preparation of tyrosine kinase inhibitors. And the patent contained the following:
The present invention relates to tyrosine kinase inhibitors I [wherein Z1 and Z2 = independently N or (un)substituted CH; with the proviso that at least one of Z1 and Z2 is N; X = absence, O, S, (un)substituted CH or NH; Y = O, S, (un)substituted CH or NH; A = (un)substituted aryl, heteroaryl, heterocyclyl, or cycloalkyl; B and C = independently absence, (un)substituted ring or fused ring], pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof. The compounds of the present invention can be used as tyrosine kinase inhibitors, or used to reduce or inhibit the activity of EGFR or mutants thereof (for example, EGFR mutants containing T790M mutation) in cells, or used to treat and/or prevent diseases (for example, cancer) related to overactivity of EGFR, especially drug-resistant diseases (for example, cancer) caused by mutation of EGFR (for example, T790M mutation of EGFR). For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 5.7 nM against EGFR T790. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Synthetic Route of 74904-29-3
The Article related to preparation tyrosine kinase inhibitor treatment cancer egfr human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 74904-29-3
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem